Skip to main content Accessibility help
×
Home

Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI

Published online by Cambridge University Press:  01 February 2008

Stephen Salloway
Affiliation:
Department of Clinical Neurosciences, Brown Medical School, Rhode Island, U.S.A. Department of Psychiatry and Human Behavior, Brown Medical School, Rhode Island, U.S.A. Memory and Aging Program, Butler Hospital, Providence, Rhode Island, U.S.A.
Stephen Correia
Affiliation:
Department of Psychiatry and Human Behavior, Brown Medical School, Rhode Island, U.S.A. Memory and Aging Program, Butler Hospital, Providence, Rhode Island, U.S.A.
Sharon Richardson
Affiliation:
Eisai Inc, Teaneck, New Jersey, U.S.A.
Corresponding
E-mail address:

Abstract

Objective: This paper reviews the key lessons learned from the first published short-term, placebo-controlled trial of a cholinesterase inhibitor for treatment of mild cognitive impairment (MCI).

Methods: The study was a 24-week placebo-controlled trial designed to evaluate the efficacy and safety of donepezil HCl (donepezil) in the treatment of cognitive impairment in subjects with MCI. Primary outcome measures were the NYU Paragraphs Test and the ADCS Clinicians Global-Impression of Change in the intent-to-treat last-observation-carried-forward group.

Results: There was no benefit of donepezil treatment on primary outcome measures (NYU Paragraphs and ADCS CGI-C) in the ITT-LOCF group but positive findings were seen on NYU Paragraphs in the fully evaluable group and in certain secondary outcome measures across both groups.

Conclusions: The results highlight the need for the use of primary cognitive and functional measures that are reliable and sensitive to change in patients with MCI. Measures of episodic memory, psychomotor speed and complex attention were most sensitive in this study. Functional rating scales are needed that measure change in individual subjects' key areas of functional deficit, which typically involve executive aspects of instrumental ADLs. Tolerability can be increased by use of flexible dosing and efficacy is likely to be enhanced by increasing the length of the trial from six to 12 months and by enriching the sample with subjects more likely to decline during the trial.

Type
MCI CONFERENCE PAPER
Copyright
Copyright © International Psychogeriatric Association 2007

Access options

Get access to the full version of this content by using one of the access options below.

References

Folstein, M., Folstein, E. and McHugh, P. 1975. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189198.CrossRefGoogle ScholarPubMed
Grundman, M. et al. 2004. Mild Cognitive Impairment can be distinguished from Alzheimer's disease and normal aging for clinical trials. Archives of Neurology, 61, 5966.CrossRefGoogle ScholarPubMed
Kluger, A., Ferris, S. H., Golomb, J., Mittelman, M. S. and Reisberg, B. 1999. Neuropsychological prediction of decline to dementia in nondemented elderly. Journal of Geriatric Psychiatry and Neurology, 12, 168179.CrossRefGoogle ScholarPubMed
Mohs, R. C. and Cohen, L. 1988. Alzheimer's. Disease Assessment Scale (ADAS). Psychopharmacology Bulletin, 24, 627628.Google Scholar
Mohs, R. C. et al. 1997. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. Alzheimer Disease and Associated Disorders, 11 (Suppl 2), S13S21.CrossRefGoogle ScholarPubMed
Morris, J. C. 1993. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology, 43, 24122414.CrossRefGoogle ScholarPubMed
Petersen, R., Grundman, M., Thomas, R. and Thal, L. 2004. Donepezil and vitamin E as treatments for mild cognitive impairment. Neurobiology of Aging, 25, S20.CrossRefGoogle Scholar
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G. and Kokmen, E. 1999. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology, 56, 303308.CrossRefGoogle ScholarPubMed
Salloway, S. et al. 2004. Efficacy of donepezil in mild cognitive impairment: a randomized. placebo-controlled trial. Neurology, 63, 651657.CrossRefGoogle ScholarPubMed
Schneider, L. S. et al. 1997. Validity and reliability of the Alzheimer Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Disease and Associated Disorders, 11 (Suppl. 2), S22S32.CrossRefGoogle ScholarPubMed
Smith, A. 1982. Symbol Digit Modalities Test. Los Angeles: Western Psychological Service.Google Scholar
Wechsler, D. 1987. Wechsler Memory Scale – Revised. San Antonio: Psychological Corporation.Google Scholar

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 3
Total number of PDF views: 40 *
View data table for this chart

* Views captured on Cambridge Core between September 2016 - 23rd January 2021. This data will be updated every 24 hours.

Hostname: page-component-76cb886bbf-4qfsd Total loading time: 0.262 Render date: 2021-01-23T15:45:05.249Z Query parameters: { "hasAccess": "0", "openAccess": "0", "isLogged": "0", "lang": "en" } Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false }

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *